Examining EML4-ALK variants in the clinical setting: the next frontier?

The discovery of the fusion of anaplastic lymphoma kinase (ALK) with echinoderm microtubule-associated protein like 4 (EML4) and the resulting oncoprotein with a valuable clinical target has dramatically improved the survival trajectory in 4–7% of patients with non-small cell lung cancer (NSCLC) over the last decade.